Skip to main content
. 2021 Dec 6;11(12):195. doi: 10.1038/s41408-021-00591-4

Table 1.

The demographics and treatment characteristics of patients.

graphic file with name 41408_2021_591_Tab1_HTML.gif

CMT chemotherapy, auto-SCT autologous stem cell transplantation, allo-SCT allogeneic stem cell transplantation, DA daunorubicin and cytarabine, IA idarubicin and cytarabine, ‘3 + 3’ daunorubicin or idarubicin 10 mg/m2 per day on days 1–3 and cytarabine 2.0 g/m2 twice daily on days 1–3, CR complete remission, CR1 first CR, MRD measurable residual disease, MRD1 MRD after one course of chemotherapy, MRD2 MRD after two courses of chemotherapy, MRD3 MRD after three courses of chemotherapy.